{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T18:52:29Z","timestamp":1786474349182,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40261-025-01481-4","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:14:53Z","timestamp":1757596493000},"page":"781-791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-Dose Propranolol versus Amitriptyline for Episodic Migraine Prophylaxis: A Randomized Controlled Trial Assessing Efficacy, Safety, and Cost-Effectiveness"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-3916","authenticated-orcid":false,"given":"Vandana","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasra","family":"Banu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-9970","authenticated-orcid":false,"given":"Girish Gulab","family":"Meshram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-5438","authenticated-orcid":false,"given":"Debashish","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"4","key":"1481_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631\u201349.","journal-title":"Neurol Clin"},{"key":"1481_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108400","volume":"243","author":"M Roghani","year":"2024","unstructured":"Roghani M, Ghaedi G, Iranzadeh S, Golezar MH, Afshinmajd S. Efficacy and safety of venlafaxine versus nortriptyline for the preventive treatment of migraine: a double-blind randomized clinical trial. Clin Neurol Neurosurg. 2024;243:108400.","journal-title":"Clin Neurol Neurosurg"},{"issue":"10203","key":"1481_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4. (2019 Aug 16. Erratum. In: Lancet. 2019 Oct 29:S0140-6736(19)32643-1. doi: 10.1016\/S0140-6736(19)32643-1).","journal-title":"Lancet"},{"issue":"2","key":"1481_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1212\/CON.0000000000001418","volume":"30","author":"RB Lipton","year":"2024","unstructured":"Lipton RB. Preventive treatment of migraine. Continuum (Minneap Minn). 2024;30(2):364\u201378.","journal-title":"Continuum (Minneap Minn)."},{"issue":"1","key":"1481_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1.","journal-title":"J Headache Pain"},{"issue":"1","key":"1481_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-015-0496-6","volume":"16","author":"M Linde","year":"2015","unstructured":"Linde M, Steiner TJ, Chisholm D. Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain. 2015;16(1):15. https:\/\/doi.org\/10.1186\/s10194-015-0496-6.","journal-title":"J Headache Pain"},{"issue":"2","key":"1481_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","volume":"15","author":"T Sprenger","year":"2018","unstructured":"Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):313\u201323. https:\/\/doi.org\/10.1007\/s13311-018-0621-8.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1481_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4103\/jfmpc.jfmpc_927_23","volume":"13","author":"KM Patel","year":"2024","unstructured":"Patel KM, Popatbhai KM, Xavier R, Aramin MAS, Faris KJF, Mateen MA, et al. Comparison of the efficacy of propranolol versus amitriptyline as monotherapy for prophylaxis of migraine. J Family Med Prim Care. 2024;13(2):699\u2013703. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_927_23.","journal-title":"J Family Med Prim Care"},{"key":"1481_CR9","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. https:\/\/doi.org\/10.1177\/0333102417738202. (PMID: 29368949).","DOI":"10.1177\/0333102417738202"},{"issue":"3","key":"1481_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1526-4610.1981.hed2103105.x","volume":"21","author":"NT Mathew","year":"1981","unstructured":"Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache. 1981;21(3):105\u20139. https:\/\/doi.org\/10.1111\/j.1526-4610.1981.hed2103105.x. (PMID: 7021472).","journal-title":"Headache"},{"issue":"6","key":"1481_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jpainsymman.2010.08.016","volume":"41","author":"MJ Hjermstad","year":"2011","unstructured":"Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41(6):1073\u201393. https:\/\/doi.org\/10.1016\/j.jpainsymman.2010.08.016. (PMID: 21621130).","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"1481_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963\u201374. https:\/\/doi.org\/10.1023\/a:1026119331193. (PMID: 14651415).","journal-title":"Qual Life Res"},{"key":"1481_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/b:qlir.0000117276.27373.53","volume":"13","author":"SM Skevington","year":"2004","unstructured":"Skevington SM, Lotfy M, O\u2019Connell KA. The World Health Organization\u2019s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299\u2013309. https:\/\/doi.org\/10.1023\/b:qlir.0000117276.27373.53. (PMID: 15079211).","journal-title":"Qual Life Res"},{"key":"1481_CR14","unstructured":"World Health Organization, Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment [Internet]. Uppsala: Uppsala Monitoring Centre; [cited 2024 Aug 1]. Available from: https:\/\/www.who-umc.org\/pharmacovigilance\/activities\/methodologies\/causality_assessment\/. Accessed 20 Jan 2025."},{"key":"1481_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/ajhp\/49.4.941","volume":"49","author":"SC Hartwig","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992Apr;49:941\u20138. https:\/\/doi.org\/10.1093\/ajhp\/49.4.941. (PMID: 1571884).","journal-title":"Am J Hosp Pharm"},{"key":"1481_CR16","first-page":"166","volume":"4","author":"H Singh","year":"2021","unstructured":"Singh H. Efficacy of amitriptyline versus propranolol for prophylaxis of migraine: a comparative study. Int J Heal Clin Res. 2021;4:166\u20139.","journal-title":"Int J Heal Clin Res"},{"issue":"2","key":"1481_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3329\/jcamr.v6i2.42698","volume":"6","author":"MA Islam","year":"2019","unstructured":"Islam MA, Dahlia S, Shahi MS, Hassan MS. Comparison of propranolol and amitriptyline as monotherapy for migraine prophylaxis. J Curr Adv Med Res. 2019;6(2):77\u201382. https:\/\/doi.org\/10.3329\/jcamr.v6i2.42698.","journal-title":"J Curr Adv Med Res"},{"key":"1481_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.22159\/ijpps.2022v14i7.44151","volume":"14","author":"D Jyothi","year":"2022","unstructured":"Jyothi D, Jaju S, Karunasree N. To evaluate the efficacy, safety and tolerability of oral propranolol comparison with oral amitriptyline for migraine prophylaxis. Int J Pharm Pharm Sci. 2022;14:31\u20135. https:\/\/doi.org\/10.22159\/ijpps.2022v14i7.44151.","journal-title":"Int J Pharm Pharm Sci"},{"issue":"S1","key":"1481_CR19","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.53730\/ijhs.v6nS1.6578","volume":"6","author":"DR Gorukanti","year":"2022","unstructured":"Gorukanti DR, Rajneesh V, Sumalatha N, Karunakar CH. Comparison of propranolol versus amitriptyline as monotherapy for migraine prophylaxis. Int J of Health Sci. 2022;6(S1):7379\u201387. https:\/\/doi.org\/10.53730\/ijhs.v6nS1.6578.","journal-title":"Int J of Health Sci."},{"issue":"3","key":"1481_CR20","first-page":"86","volume":"12","author":"M Raza","year":"2022","unstructured":"Raza M. Propranolol versus amitriptyline for prophylaxis: a prospective study. Eur J Cardiovasc Med. 2022;12(3):86\u201390.","journal-title":"Eur J Cardiovasc Med"},{"issue":"5","key":"1481_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/archneur.1987.00520170016015","volume":"44","author":"DK Ziegler","year":"1987","unstructured":"Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol. 1987;44(5):486\u20139. https:\/\/doi.org\/10.1001\/archneur.1987.00520170016015. (PMID: 3579659).","journal-title":"Arch Neurol"},{"issue":"1","key":"1481_CR22","first-page":"93","volume":"22","author":"A Israil","year":"2013","unstructured":"Israil A, Ahmed S, Rahman KM, Uddin MJ, Dey SK, Battacharjee M, et al. Efficacy of amitriptyline, pizotifen and propranolol in the prevention of migraine. Mymensingh Med J. 2013Jan;22(1):93\u2013100 (PMID: 23416816).","journal-title":"Mymensingh Med J"},{"issue":"4\u20135","key":"1481_CR23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/03331024211047454","volume":"42","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury D, Bansal L, Duggal A, Datta D, Mundra A, Krishnan A, et al. TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia. 2022;42(4\u20135):396\u2013408. https:\/\/doi.org\/10.1177\/03331024211047454. (Epub 2021 Sep 27. PMID: 34579560).","journal-title":"Cephalalgia"},{"issue":"3","key":"1481_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","volume":"31","author":"DW Dodick","year":"2009","unstructured":"Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31(3):542\u201359. https:\/\/doi.org\/10.1016\/j.clinthera.2009.03.020. (PMID: 19393844).","journal-title":"Clin Ther"},{"issue":"2","key":"1481_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108\u201318. https:\/\/doi.org\/10.1177\/03331024211053571. (Epub 2021 Nov 7. PMID: 34743579; PMCID: PMC8793299).","journal-title":"Cephalalgia"},{"issue":"8","key":"1481_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/11531180-000000000-00000","volume":"24","author":"J Yu","year":"2010","unstructured":"Yu J, Smith KJ, Brixner DI. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. CNS Drugs. 2010;24(8):695\u2013712. https:\/\/doi.org\/10.2165\/11531180-000000000-00000. (PMID: 20658800).","journal-title":"CNS Drugs"},{"key":"1481_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100241","volume":"16","author":"D Sharma","year":"2023","unstructured":"Sharma D, Prinja S, Aggarwal AK, Rajsekar K, Bahuguna P. Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment. The Lancet Regional Health. 2023;16:100241. https:\/\/doi.org\/10.1016\/j.lansea.2023.100241. (PMID: 37694178; PMCID: PMC10485782).","journal-title":"The Lancet Regional Health"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01481-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:36:38Z","timestamp":1758972998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01481-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01481-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study data are stored in Microsoft Excel format and can be provided by the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material (Data Transparency)"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Maulana Azad Medical College and Associated Hospitals (Date: 20 September 2019; approval no. 17\/IEC\/MAMC\/2019).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Roy V. contributed to the conception and design of the study, supervised the project, contributed to data interpretation, and critically revised the manuscript. Banu N. was responsible for data acquisition, performing the statistical analysis, and contributed to data interpretation. Chowdhury D. provided the clinical patient data and contributed to data interpretation. Meshram G.G. drafted the manuscript, prepared the graphs and tables, and contributed to data interpretation. All authors have read and approved the final manuscript and agree to be accountable for all aspects of the work to ensure its accuracy and integrity.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}